

P Richard Harrigan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8440844/publications.pdf>

Version: 2024-02-01

46
papers

2,119
citations

279487

23
h-index

233125

45
g-index

47
all docs

47
docs citations

47
times ranked

3280
citing authors

#	ARTICLE	IF	CITATIONS
1	Intra-host evolutionary dynamics of the hepatitis C virus among people who inject drugs. <i>Scientific Reports</i> , 2021, 11, 9986.	1.6	1
2	SHARED: An International Collaboration to Unravel Hepatitis C Resistance. <i>Viruses</i> , 2021, 13, 1580.	1.5	6
3	Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay. <i>Viruses</i> , 2021, 13, 1721.	1.5	1
4	Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 170-182.	1.3	50
5	HIV-1 phylodynamic analysis among people who inject drugs in Pakistan correlates with trends in illicit opioid trade. <i>PLoS ONE</i> , 2020, 15, e0237560.	1.1	4
6	Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	1
7	Are We Ready for NGS HIV Drug Resistance Testing? The Second "Winnipeg Consensus" Symposium. <i>Viruses</i> , 2020, 12, 586.	1.5	18
8	Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework. <i>Viruses</i> , 2020, 12, 645.	1.5	7
9	Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping. <i>Viruses</i> , 2020, 12, 694.	1.5	34
10	Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. <i>Scientific Reports</i> , 2020, 10, 1634.	1.6	45
11	Mitochondrial DNA somatic mutation burden and heteroplasmy are associated with chronological age, smoking, and HIV infection. <i>Aging Cell</i> , 2019, 18, e13018.	3.0	27
12	A systematic review of the genetic mechanisms of dolutegravir resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3135-3149.	1.3	95
13	Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP. <i>Antiviral Therapy</i> , 2019, 24, 211-220.	0.6	2
14	Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz060.	0.4	11
15	Phylogenetic surveillance of travel-related Zika virus infections through whole-genome sequencing methods. <i>Scientific Reports</i> , 2019, 9, 16433.	1.6	4
16	A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. <i>Infection, Genetics and Evolution</i> , 2019, 69, 76-84.	1.0	6
17	Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity. <i>Journal of Virology</i> , 2019, 93, .	1.5	17
18	Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing-optimization study of current HIV antiretroviral regimens. <i>Antiviral Research</i> , 2018, 159, 45-54.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Bioinformatic data processing pipelines in support of next-generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus. <i>Journal of the International AIDS Society</i> , 2018, 21, e25193.	1.2	34
20	Phylogenetic approach to recover integration dates of latent HIV sequences within-host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8958-E8967.	3.3	50
21	Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005–2013. <i>AIDS Patient Care and STDs</i> , 2018, 32, 257-264.	1.1	13
22	Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996–2013: a modelling study. <i>Lancet HIV</i> , 2017, 4, e303-e310.	2.1	31
23	Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada. <i>PLoS ONE</i> , 2017, 12, e0184848.	1.1	5
24	Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion. <i>Aging</i> , 2017, 9, 687-705.	1.4	31
25	The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. <i>Lancet Infectious Diseases</i> , 2016, 16, 698-702.	4.6	41
26	Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. <i>Journal of Hepatology</i> , 2016, 64, 1247-1255.	1.8	18
27	Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study. <i>Lancet HIV</i> , 2016, 3, e231-e238.	2.1	168
28	Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic. <i>Journal of Virology</i> , 2016, 90, 1244-1258.	1.5	13
29	Increased Prevalence of Controlled Viremia and Decreased Rates of HIV Drug Resistance Among HIV-Positive People Who Use Illicit Drugs During a Community-wide Treatment-as-Prevention Initiative. <i>Clinical Infectious Diseases</i> , 2016, 62, 640-647.	2.9	35
30	The Impact of Clinical, Demographic and Risk Factors on Rates of HIV Transmission: A Population-based Phylogenetic Analysis in British Columbia, Canada. <i>Journal of Infectious Diseases</i> , 2015, 211, 926-935.	1.9	89
31	Global Origin and Transmission of Hepatitis C Virus Nonstructural Protein 3 Q80K Polymorphism. <i>Journal of Infectious Diseases</i> , 2015, 211, 1288-1295.	1.9	44
32	Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) Cohort. <i>International Journal of Epidemiology</i> , 2015, 44, 58-67.	0.9	31
33	Deep Sequencing Accuracy and Reproducibility Using Roche/454 Technology for Inferring Co-Receptor Usage in HIV-1. <i>PLoS ONE</i> , 2014, 9, e99508.	1.1	10
34	GWATCH: a web platform for automated gene association discovery analysis. <i>GigaScience</i> , 2014, 3, 18.	3.3	5
35	Genotypic and Functional Impact of HIV-1 Adaptation to Its Host Population during the North American Epidemic. <i>PLoS Genetics</i> , 2014, 10, e1004295.	1.5	45
36	Theoretical and experimental assessment of degenerate primer tagging in ultra-deep applications of next-generation sequencing. <i>Nucleic Acids Research</i> , 2014, 42, e98-e98.	6.5	29

#	ARTICLE	IF	CITATIONS
37	Temporal trends in the discontinuation of first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2202-2209.	1.3	24
38	Significance and Clinical Management of Persistent Low-Level Viremia and Very-Low-Level Viremia in HIV-1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3585-3598.	1.4	105
39	Early Initiation of Combination Antiretroviral Therapy in HIV-1-Infected Newborns Can Achieve Sustained Virologic Suppression With Low Frequency of CD4+ T Cells Carrying HIV in Peripheral Blood. <i>Clinical Infectious Diseases</i> , 2014, 59, 1012-1019.	2.9	77
40	Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The "HIV Treatment as Prevention" Experience in a Canadian Setting. <i>PLoS ONE</i> , 2014, 9, e87872.	1.1	272
41	Blood mitochondrial DNA mutations in HIV-infected women and their infants exposed to HAART during pregnancy. <i>Aids</i> , 2012, 26, 675-683.	1.0	17
42	Predicting HIV Coreceptor Usage on the Basis of Genetic and Clinical Covariates. <i>Antiviral Therapy</i> , 2007, 12, 1097-1106.	0.6	137
43	Predictors of HIV Drug Resistance Mutations in a Large Antiretroviral-Naive Cohort Initiating Triple Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 191, 339-347.	1.9	386
44	HIV-1 Drug Resistance: Degree of Underestimation by a Cross-Sectional versus a Longitudinal Testing Approach. <i>Journal of Infectious Diseases</i> , 2005, 191, 1325-1330.	1.9	42
45	Association of the CCR5 ^{Δ32} Mutation with Clinical Response and >5-year Survival following Initiation of First Triple Antiretroviral Regimen. <i>Antiviral Therapy</i> , 2005, 10, 849-853.	0.6	7
46	Prevalence and clinical implications of insertions in the HIV-1 p6 ^{Gag} N-terminal region in drug-naive individuals initiating antiretroviral therapy. <i>Antiviral Therapy</i> , 2003, 8, 91-96.	0.6	16